Chemotherapy-induced peripheral neurotoxicity: a critical analysis (Q27010318)

David Goldstein

2

1 reference

Arun V. Krishnan

3

1 reference

Cindy S-Y Lin

4

1 reference

Michael L. Friedlander

5

1 reference

James Cassidy

6

1 reference

Martin Koltzenburg

7

1 reference

language of work or name

1 reference

2013

1 reference

1 reference

63

1 reference

PubMed

issue

6

1 reference

PubMed

page(s)

419-37

1 reference

Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies

PubMed

cites work

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Permeation of proteins from the blood into peripheral nerves and ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide-induced neuropathy: a ganglionopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Evidence for direct axonal toxicity in vincristine neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Paraneoplastic disorders of the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

An update on monoclonal gammopathy and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Neuropathy and paraproteins: review of a complex association

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Peripheral nerve damage associated with administration of taxanes in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Paclitaxel drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Persistent mobility disability after neurotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Acute oxaliplatin-induced peripheral nerve hyperexcitability

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Impact of oxaliplatin-induced neuropathy: a patient perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Longitudinal assessment of oxaliplatin-induced neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Persistent neuropathy after treatment with cisplatin and oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Long-term platinum retention after treatment with cisplatin and oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Long-term effects of vincristine on the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Vincristine-induced autonomic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Guillain-Barré syndrome in a child with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

21 January 2018

Guillain–Barré Syndrome

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide and sensory neurotoxicity: a neurophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Bortezomib-induced severe autonomic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Immune-mediated neuropathies in myeloma patients treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21204